Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa Treatment

Part of paid clinical trials in Hershey, Pennsylvania.

Sponsor
Milton S. Hershey Medical Center
Study ID
NCT04414514
Phase
PHASE2
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
12 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

Investigators hypothesize that ruxolitinib 1.5% cream is an effective therapy for HS participants through inhibition of inflammatory activity. Investigators aim to: * Demonstrate the clinical efficacy of ruxolitinib 1.5% cream in decreasing the clinical disease activity after 16 weeks of treatment. * Investigate the impact of ruxolitinib 1.5% cream on skin inflammation through translational analyses of skin biopsy samples.

Key Dates

Start date
Oct 13, 2022
Status verified
Aug 2025
Primary completion
Feb 23, 2024
Completion
Feb 23, 2024

Study Design

Enrollment
6 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Open-label
    Topical Ruxolitinib 1.5% Cream, twice daily for 16 weeks

Primary Outcome Measure

Number of Participants With Hidradenitis Suppurativa Clinical Response (HiSCR) [ Time Frame: 16 weeks after treatment. ]

Locations (1)

FacilityCityStateZIPSite coordinators
Penn State Hershey Medical CenterHersheyPennsylvania17033-

Find similar trials in Hershey, PA

By condition
Hidradenitis suppurativa
By specialty
DermatologyRheumatologyAutoimmune disease
By research site
Penn State Hershey Medical Center· Hershey, PA

Related Studies